Every executable definition, side-panel definition and catalogue entry, in three groups by the licence of its
source, with its threshold in our own words and the source it is cited to. All are drafts pending review; a definition shows as reviewed only when both a clinical and a coding
approval are recorded. Default set library_default_set@1.1.
Local criteria: site choices among published definitions and named local
variants of the side-panel definitions, each with a change record, two approvals and an outcome preview.
∅Retired: removed from the default set (copyrighted
with a permissive replacement, superseded, or a grading scale rather than a definition). Kept so that stored checks still replay.
Setting: show extended capabilities on clinician screens
Current on clinician screens: Off (default)
When on, findings from extended definitions appear on the side panel and the per-note screen under their own heading, after the core
findings. Off or on, every check runs and replays the same, and the coder view shows both groups. The guided demo's four cases are unaffected.
Thresholds are stated in our own words. Verbatim text is kept only from U.S. government works and openly licensed (CC BY)
sources, with the attribution the licence asks for; copyrighted guidelines are cited by title, body and year, with a locator.
No endorsement by the cited bodies is implied. This is not legal advice: counsel should review before commercial release.
Cancer-treatment adverse-event grading scale (NCI CTCAE): off by default
CTCAE grades describe adverse events in people receiving cancer treatment, usually in trials; they are not diagnostic criteria, and several grades depend on the laboratory reference range or on clinical descriptors that are not encoded. Using them outside that setting is a local decision for the clinical reviewer.
Current: Off (default)
When on, grading entries are shown only as "another published definition gives …" or as values needing clinical judgement; they never
raise a "not stated" item.
CDI or coding staff can change this setting. A clinician account records clinical reviews; a coding or documentation account records coding reviews: switch the demo user.
8 of 8 in “Retired” shown · open an entry for its source, threshold and review.
Severe hypercholesterolaemia, LDL-C ≥190 mg/dL (2018 AHA/ACC cholesterol guideline)aha2018_severe_hypercholesterolaemia@1.01RetiredDraft · pending reviewdraft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Severe hypercholesterolaemia
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default: Retired (licence_status 'retired'): copyrighted society guideline; same 190 mg/dL boundary as ATP III 'very high'.
Edition
2018 (2018)
Second source
National Heart, Lung, and Blood Institute, National Cholesterol Education Program (NIH Publication No. 01-3670) 2001 · agrees: ATP III calls ≥190 mg/dL 'very high'.
Contested
no: Same 190 mg/dL boundary as ATP III 'very high'.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
aha2018_severe_hypercholesterolaemia@1.0
In our words: LDL cholesterol 190 mg/dL (4.9 mmol/L) or higher in adults.
American Heart Association / American College of Cardiology and partner societies (2018) · Section 4.2 heading; Top 10 Take-Home Message 4 · source
retired: Retired as a separate primary: copyrighted society guideline. The same 190 mg/dL boundary is the 'very high' class of the federal ATP III classification (atp3_ldl@1.0). Making atp3_ldl the default for the LDL family also counts 130 to 189 mg/dL as present, which is a clinical decision; until then the LDL family has no default definition (default_set@1.1). No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Lymphopenia
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
none opened · not found: No independent body publishes these grades: CTCAE is the sole definer of its own grading scale. CTCAE v5.0 (same body, not independent) was compared and gives the same numeric thresholds for this term.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ctcae5_lymphopenia@1.0
In our words: Cancer-treatment adverse-event grade, not a diagnosis. Grade 4 (by laboratory value); Grade 3 (by laboratory value); Grade 2 (by laboratory value); Grade 1 (by laboratory value); At or above the laboratory LLN
Grade 1: <LLN - 800/mm3; <LLN - 0.8 x 10e9/L. Grade 2: <800 - 500/mm3; <0.8 - 0.5 x 10e9 /L. Grade 3: <500 - 200/mm3; <0.5 - 0.2 x 10e9 /L. Grade 4: <200/mm3; <0.2 x 10e9 /L
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) (2017) · PDF page 88 (5x7 quick reference), term 'Lymphocyte count decreased' (published November 27, 2017) · source
retired: Retired: CTCAE v5.0 is superseded by v6.0 and was never run. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Neutropenia
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · disagrees: CTCAE v6.0 (same body, not independent) shifted the bands (grade 4 <100/mm3). No independent body grades neutropenia on this scale.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ctcae5_neutropenia@1.0
In our words: Cancer-treatment adverse-event grade, not a diagnosis. Grade 4 (by laboratory value); Grade 3 (by laboratory value); Grade 2 (by laboratory value); Grade 1 (by laboratory value); At or above the laboratory LLN
Grade 1: <LLN - 1500/mm3; <LLN - 1.5 x 10e9 /L. Grade 2: <1500 - 1000/mm3; <1.5 - 1.0 x 10e9 /L. Grade 3: <1000 - 500/mm3; <1.0 - 0.5 x 10e9 /L. Grade 4: <500/mm3; <0.5 x 10e9 /L
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) (2017) · PDF page 88 (5x7 quick reference), term 'Neutrophil count decreased' (published November 27, 2017) · source
retired: Retired: CTCAE v5.0 is superseded by v6.0 and was never run. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Thrombocytopenia
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default
Edition
v5.0 (2017) (a newer edition exists)
Second source
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) 2025 · disagrees: CTCAE v6.0 (same body, not independent) moved the grade 3/4 boundary to 10,000/mm3.
Contested
no: Grading scale of a single body; not a diagnostic definition. Other bodies define this condition with different numbers (see second source where one was opened).
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ctcae5_thrombocytopenia@1.0
In our words: Cancer-treatment adverse-event grade, not a diagnosis. Grade 4 (by laboratory value); Grade 3 (by laboratory value); Grade 2 (by laboratory value); Grade 1 (by laboratory value); At or above the laboratory LLN
Grade 1: <LLN - 75,000/mm3; <LLN - 75.0 x 10e9 /L. Grade 2: <75,000 - 50,000/mm3; <75.0 - 50.0 x 10e9 /L. Grade 3: <50,000 - 25,000/mm3; <50.0 - 25.0 x 10e9 /L. Grade 4: <25,000/mm3; <25.0 x 10e9 /L
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) (2017) · PDF page 89 (5x7 quick reference), term 'Platelet count decreased' (published November 27, 2017) · source
retired: Retired: CTCAE v5.0 is superseded by v6.0 and was never run. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
Clinical review: none recorded yet.
Coding review: none recorded yet.
Vitamin D deficiency and insufficiency by 25(OH)D (Endocrine Society 2011)es2011_vitamin_d@1.01RetiredDraft · pending reviewdraft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Vitamin D deficiency
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default: Retired (licence_status 'retired'): copyrighted, misprint and gap in the printed ranges; the 2024 edition declined to set a target.
Edition
2011 (2011) (a newer edition exists)
Second source
Institute of Medicine committee (J Clin Endocrinol Metab 2011;96:53-58) 2011 · disagrees: IOM treats 20 ng/mL as sufficient for 97.5% of the population, so 20-29 ng/mL is not 'insufficient' by IOM; encoded separately as iom2011_vitamin_d.
Contested
yes: Thresholds disagree between bodies: the IOM (2011) found 20 ng/mL (50 nmol/L) covers the needs of 97.5% of the population and warned that inadequacy was overestimated; the Endocrine Society 2011 called <20 deficiency and 21-29 insufficiency; the Endocrine Society 2024 declined to set a target level.
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline
es2011_vitamin_d@1.0
In our words: 25(OH)D below 20 ng/mL called deficient and 21 to 29 ng/mL insufficient (contested).
Endocrine Society (2011) · Recommendation 1.2 · source
retired: Retired: copyrighted; the printed ranges contain a misprint and a gap; the society's 2024 edition declined to set a target level. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
Clinical review: none recorded yet.
Coding review: none recorded yet.
Adult overweight and obesity by BMI (WHO fact sheet)who_adult_bmi@1.01RetiredDraft · pending reviewdraft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Obesity / overweight
Tier
1
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
not run by default: Retired (licence_status 'retired'): duplicates cdc_adult_bmi at 25 and 30; WHO non-commercial licence.
Edition
fact sheet dated 7 October 2026 (2026)
Second source
Centers for Disease Control and Prevention 2024 · agrees: Same cut-offs; CDC applies them from age 20.
Contested
yes: As for cdc_adult_bmi: population-specific cut-offs and the limits of BMI as a measure of adiposity.
Obesity and overweight (fact sheet)
who_adult_bmi@1.0
In our words: Adult body-mass index 25 or more is overweight; 30 or more is obesity.
World Health Organization (2026) · Definitions for adults · source
retired: Retired: duplicates the federal CDC categories at 25 and 30 (cdc_adult_bmi@1.0); WHO publications carry a non-commercial licence. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
Clinical review: none recorded yet.
Coding review: none recorded yet.
Thyroid stimulating hormone increased (CTCAE v5.0) and thyroid dysfunction by TSHctcae5_tsh_increasedcatalogueRetiredDraft · pending reviewdraft — pending clinical and coding review
Status
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Thyroid dysfunction
Tier
2
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
catalogue (not executable)
Edition
2017
Why not executable
TSH thresholds depend on the laboratory reference range, age and pregnancy, and hypothyroidism/hyperthyroidism also need free T4/T3 and clinical context. CTCAE v5.0 grades only 'TSH increased and no intervention initiated' (grade 1) and sends anything treated to 'Hypothyroidism'. Without the laboratory range and free hormone levels the answer would be 'not assessable', so no executable entry is offered. No guideline with fixed TSH cut-offs was opened.
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ctcae5_tsh_increased
In our words: Adverse-event grade by management, not by value; nothing executable.
TSH increased and no intervention initiated
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) (2017) · PDF page 89 (5x7 quick reference), term 'Thyroid stimulating hormone increased' (published November 27, 2017) · source
retired: Retired with the CTCAE entries: an adverse-event grading scale for cancer treatment, not a diagnostic definition. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.
draft — pending clinical and coding review (draft — requires clinical and coding review)
Condition
Hypophosphataemia
Tier
2
Licence
Retired
Source checked
opened on 2026-11-14: Opened by the build that encoded this entry; the threshold matches the opened text.
Use here
catalogue (not executable)
Edition
2025
Why not executable
CTCAE v6.0 grades hypophosphataemia by management, not by value: grade 1 'Laboratory finding only and intervention not indicated', grade 2 'Oral replacement therapy indicated', grade 3 hospitalisation, grade 4 life-threatening. No numeric threshold to execute. No other numeric definition was opened.
Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0)
ctcae6_hypophosphataemia
In our words: Adverse-event grade by management, not by value; nothing executable.
Grade 1: Laboratory finding only and intervention not indicated. Grade 2: Oral replacement therapy indicated
National Cancer Institute, Cancer Therapy Evaluation Program (U.S. Department of Health and Human Services) (2025) · PDF page 181, term 'Hypophosphatemia' (published July 22, 2025) · source
retired: Retired with the CTCAE entries: an adverse-event grading scale for cancer treatment, not a diagnostic definition. No endorsement by the cited bodies is implied.
Review
Reviewed only when both a clinical review and a coding review are recorded as approved.